Esophageal cancer secondary prevention
|
Esophageal cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Esophageal cancer secondary prevention On the Web |
|
American Roentgen Ray Society Images of Esophageal cancer secondary prevention |
|
Risk calculators and risk factors for Esophageal cancer secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Hadeel Maksoud M.D.[2]
Overview
Secondary prevention may be effective in reducing the incidence of esophageal cancer, if treated early at the dysplasia stage with monoclonal antibody therapy. At present, there is no particular program in place to reduce the incidence of esophageal cancer.
Secondary Prevention
- Secondary prevention can be effective in high risk groups whom frequently smoke and drink alcohol if they are treated early enough in the dysplastic change before cancer occurs.[1]
- A study was carried out in Hishun village, China.
- Due to different dietary factors, the incidence of esophageal cancer amongst these people was particularly high.
- Subjects were examined by esophageal exfoliative cytology
- One thrid of the participants had marked dysplasia
- antitumor B (Chinese herbs); retinamide (4-Ethoxycarbophenylretinamide) and placebo.
- The subjects with mild dysplasia were randomly divided into 2 groups for treatment with riboflavin and placebo.
- They were placed on antitumor B for 3 years
- The incidence of esophageal cancer in the antitumor B group was reduced by 53% as compared with that of the placebo group (8.3%).
- These results demonstrated that the secondary prevention of esophageal cancer is effective in the prevention of esophageal cancer.